Major healthcare investment firm Deerfield Management has fully exited its position in Lantheus Holdings (LNTH), a company focused on diagnostic imaging agents. According to a recent SEC disclosure, the fund sold its entire stake of 753,000 shares, which had been valued at $83.54 million. Deerfield is an influential investor dedicated to the healthcare sector, with interests in therapeutics, medical devices, and diagnostics.

As with all 13F filings, this disclosure reveals trades that occurred in the prior quarter. The filing, made on November 16, 2026, reflects the fund's holdings as of September 30, 2026, meaning the sale took place sometime in the third quarter. During that period, Lantheus was in the process of a pending merger with Curium, which had received an extended antitrust review from the FTC.